EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Endothelin antagonists for hypertension: has their time finally arrived?

Ernesto L Schiffrin iD

Clinical Science · 2025

DOI: 10.1042/cs20255853 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Science, 2025. Verfasst von Ernesto L Schiffrin. Beteiligte Einrichtung: Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General H…. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Endothelin Receptor Antagonists, Endothelin A Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There have been few new treatments introduced for hypertension in the last thirty years. The endothelin (ET) system was discovered in 1988, and in the following years, it was demonstrated that it participated in the elevation of blood pressure and vascular remodeling in experimental models of hypertension, particularly those with more severe forms of hypertension. Several selective and dual antagonists of ETA receptors (ETARs) and ETB receptors (ETBRs) were developed, but none reached marketing for human hypertension. Following a successful trial in resistant hypertension, a novel antihypertensive agent has been approved in Europe and in the U.S.A.: the dual ETAR/ETBR antagonist aprocitentan, which was recently approved for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Thus, the time has finally arrived for ET antagonists in hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAntihypertensive AgentsEndothelin Receptor AntagonistsEndothelin A Receptor AntagonistsEndothelinsEndothelin B Receptor AntagonistsHumansAnimalsPyrimidinesBlood PressureSulfonamidesReceptor, Endothelin A

Stichwörter der Autor:innen

bood pressureendothelinshypertensiontarget organ damagevascular remodeling

Substanzen

Antihypertensive AgentsEndothelin Receptor AntagonistsaprocitentanPyrimidinesEndothelin A Receptor AntagonistsEndothelinsSulfonamidesEndothelin B Receptor AntagonistsReceptor, Endothelin A

Autor:innen und Institutionen

  • Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, MGill University, Montreal, Quebec, Canada.

ORCID-Profile: Ernesto L Schiffrin

Zitieren

APA

Schiffrin, E. L. (2025). Endothelin antagonists for hypertension: has their time finally arrived?. Clinical Science. https://doi.org/10.1042/cs20255853

Vancouver

Schiffrin EL. Endothelin antagonists for hypertension: has their time finally arrived?. Clinical Science. 2025. doi:10.1042/cs20255853

BibTeX
@article{Schiffrin2025,
  author = {Schiffrin, Ernesto L},
  title = {Endothelin antagonists for hypertension: has their time finally arrived?},
  journal = {Clinical Science},
  year = {2025},
  doi = {10.1042/cs20255853}
}
Kostenlos starten →